Collection-image

TOPICAL COLLECTIONS

Methods and Techniques in Microbial Polysaccharide and Glycoconjugate Vaccine Research and Development

Submit Abstract

Guest Editor

Guillaume Goyette-Desjardins

Guillaume Goyette-Desjardins

University of Veterinary Medicine Hanover

Dr. Guillaume Goyette-Desjardins is a postdoctoral fellow in the laboratory of Dr. Bernd Lepenies at the University of Veterinary Medicine Hanover. He obtained his PhD in Veterinary Sciences from the University of Montreal with Dr. Mariela Segura (co-advisors Dr. Marie-Rose Van Calsteren and Dr. René Roy). During his doctoral training, he performed the purification and contributed to the determination of the capsular polysaccharide structures for eight serotypes of Streptococcus suis, one of the most important porcine bacterial pathogen and an emerging zoonotic agent. Using those newly described polysaccharides, he evaluated their antigenicity and immunogenicity in vitro and in vivo. It lead to the discovery that, unlike other serotypes of S. suis, the serotype 3 polysaccharide is highly immunogenic as it induces an opsonizing response composed of IgG and IgM. In addition, he developed for the first time a glycoconjugate vaccine composed of the serotype 2 polysaccharide conjugated to tetanus toxoid to induce a protective T-dependent antibody response. A proof of concept performed in pigs showed protection against S. suis, and more importantly, the untapped potential of glycoconjugate vaccines in the fight against invasive bacterial infections in veterinary medicine. Currently, he is interested in better understanding the influence of glycosylation patterns on protein immunogenicity. For that, he is establishing a platform of cell lines of different origins and glyco-engineered cell lines to produce various glycovariants. Subsequently, immunogenicity studies with these glycovariants will lead hopefully to the discovery of highly immunogenic glycovariants that could serve as self-adjuvanted vaccine antigens.

Collection Overview

Microbial polysaccharides, since they form the outermost layer at the surface, are important virulence factors and are the first components recognized by the immune system in the course of colonization or infection. As such, the use of polysaccharide-based vaccines and the advent of glycoconjugate vaccines have both impacted diseases caused by encapsulated pathogens. Many additional pathogen targets are currently in development following the successes in the fight against Haemophilus influenza type b, pneumococcus, and meningococcus. However, some studies are conducted with poorly purified or defined polysaccharides and many variables of glycoconjugate vaccine design heavily influence a vaccine’s immunogenicity and efficacy.

In this Methods Collection, we aim to share the latest methods and protocols employed in the context of microbial polysaccharide research to promote collaboration and disseminate key techniques and protocols from the fields of biochemistry, chemistry, and immunology. Hopefully, this will lead to a better understanding of polysaccharide and glycoconjugate immunology. The collection includes, but is not limited to, the following aspects and techniques: isolation and purification of native polysaccharides (chromatography), total synthesis and structural modification approaches by chemical, enzymatic, or physical means, conjugation to a carrier protein (glycoconjugates), and the structural (nuclear magnetic resonance, mass spectrometry) and physicochemical analyses (size exclusion chromatography with multi-angle light scattering). Additionally, cutting-edge methodologies aimed at studying polysaccharides and the antigenicity and immunogenicity of glycoconjugates are welcome for submissions.

Articles

Activation and Conjugation of Soluble Polysaccharides using 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP)
7:20

Activation and Conjugation of Soluble Polysaccharides using 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP)

0 Views

•

Cited by 9

•

2021

•